11月24日晚间，威领股份（证券代码：002667）突发公告称，因筹划控制权变更事项，股票将紧急停牌。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | 002667 | 威领股份 | Ａ 股 停牌 | 2025/11/25 | 全天 | 2025/11/26 | 2025/11/27 | 威领股份表示，公司控股股东上海领亿新材料有限公司（以下简称上海领亿）、实际控制人黄达正在筹划重大事项，该事项可能导致公司控制权发生变 更。公司股票自11月25日起停牌，预计不超过两个交易日。 值得注意的是，威领股份股价在11月24日高开高走，并在午后突然直线拉升涨停，总市值报44.04亿元。 这意味着，本次股份转让后，上海领亿对威领股份的持股比例将降至5%以下。 据悉，在筹划本次控制权转让之前，上海领亿因被动稀释、主动减持、协议转让、被动减持等原因合计持股比例已大幅下降。 特别是在2022年11月至2024年8月14日期间，上海领亿合计持股比例 ...

Core Viewpoint - Weiling Co., Ltd. is planning a change in control, leading to an emergency suspension of its stock starting November 25, 2025 [2][5]. Group 1: Control Change Announcement - Weiling Co., Ltd. announced that its controlling shareholder, Shanghai Lingyi New Materials Co., Ltd., and actual controller Huang Da are planning a significant matter that may lead to a change in the company's control [5][9]. - The company will suspend trading of its stock for a maximum of two trading days, with the stock expected to resume trading on November 27, 2025 [5]. - On November 24, 2025, Weiling's stock price surged, reaching a market capitalization of 4.404 billion yuan [5]. Group 2: Share Transfer Details - The company received notification that Shanghai Lingyi and Huang Da are planning to transfer a total of 2,023,800 shares, representing 7.7646% of the total share capital, through a private agreement [8]. - Following the share transfer, Shanghai Lingyi's holding will drop below 5%, potentially resulting in a situation where the company has no actual controller [9][11]. Group 3: Historical Shareholding Changes - Shanghai Lingyi's shareholding has significantly decreased due to various factors, including dilution and active reduction, from 23.93% in November 2022 to 12.10% as of October 24, 2025, a change of 6.39% [12][14]. - The company has faced regulatory scrutiny due to failure to report shareholding changes in a timely manner, receiving warnings from the Hunan Securities Regulatory Bureau and the Shenzhen Stock Exchange [12]. Group 4: Financial Performance - Weiling Co., Ltd. has experienced financial difficulties, reporting losses in multiple years since 2021, with net losses of 222.3 million yuan in 2023 and 308 million yuan in 2024 [15][18]. - In the first three quarters of 2025, the company achieved revenue of 213 million yuan, a year-on-year decline of 53.88%, while the net loss was reduced to 13.05 million yuan [18]. - To mitigate performance pressure, the company has expanded into other mineral sectors, acquiring a 74.3% stake in Jiayu Mining for 222 million yuan [18].

中国基金报记者 夏天 11月24日晚间， 威领股份 （证券代码：002667）突发公告称，因筹划控制权变更事项，股票将紧急停牌。 【导读】威领股份筹划控制权变更，股票11月25日起停牌 | 证券代码 | 证券简称 | 停复牌类型 | 停牌 停牌起始日 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | | 002667 | 威领股份 | A 股 停牌 | 2025/11/25 全天 | 2025/11/26 | 2025/11/27 | 威领股份表示，公司控股股东上海领亿新材料有限公司（以下简称上海领亿）、实际控制人黄达正在筹划重大事项，该事项可能导致公司 控制权发生变更。公司股票自11月25日起停牌，预计不超过两个交易日。 值得注意的是，威领股份股价在11月24日高开高走，并在午后突然直线拉升涨停，总市值报44.04亿元。 这意味着，本次股份转让后，上海领亿对威领股份的持股比例将降至5%以下。 记者回溯历史公告发现，在筹划本次控制权转让之前， 上海领亿 因被动稀释、主动减持、协议转让、被动减持等原因合计持股比例已大幅 下降。 特别是在2022年1 ...

Core Viewpoint - 威领股份 is planning to transfer shares held by its controlling shareholder, Shanghai Lingyi, and actual controller, Huang Da, which may lead to a change in control of the company [1] Group 1: Share Transfer Details - The company intends to transfer a total of 20,233,784 shares, representing 7.7646% of the total share capital, through a private agreement [1] - Upon completion of the share transfer, the acquirer will become the largest shareholder of 威领股份 [1] Group 2: Implications of the Transfer - The share transfer may result in a change of control for the company, potentially leading to a situation where the company has no actual controller [1] - The company has applied to the Shenzhen Stock Exchange for a trading suspension, effective from November 25, 2025 [1]

【导读】华锋股份拟筹划控制权变更事项 中国基金报记者 卢鸰 11月24日早间，深交所公告，广东华锋新能源科技股份有限公司拟筹划控制权变更事项，根据本所《股 票上市规则》和《上市公司自律监管指引第6号——停复牌》的有关规定，经公司申请，公司股票（证 券简称：华锋股份，证券代码：002806）于2025年11月24日开市起临时停牌。 华锋股份的董事长、控股股东、实际控制人谭帼英是一位女性高级工程师，现年75岁。曾任华南理工大 学校团委副书记、数学系党总支副书记，广东华侨信托投资公司副总经理、投资部总经理等。 华锋股份目前的主要业务为新能源汽车电控及驱动系统的研发、生产、销售以及技术服务，以及电极箔 的研发、生产、销售。 9月20日，华锋股份公告，持有公司股份812.25万股（占公司总股本比例3.82%）的股东、董事、总经理 林程，计划自公告披露之日起15个交易日后的三个月内（即2025年10月21日至2026年1月20日）以集中 竞价或大宗交易方式减持公司股份不超过203.06万股（占公司总股本比例0.96%）。 9月10日，华锋股份董事周辉以自有资金通过深圳证券交易所集中竞价交易方式增持公司股份1000股。 1 ...

Core Viewpoint - Guangdong Huafeng New Energy Technology Co., Ltd. is planning a change in control, leading to a temporary suspension of its stock trading starting November 24, 2025 [1] Group 1: Company Overview - Huafeng Co., Ltd. primarily engages in the research, production, sales, and technical services of electric control and drive systems for new energy vehicles, as well as the research, production, and sales of electrode foils [4] - The current chairman, controlling shareholder, and actual controller is Tan Guoying, a 75-year-old female senior engineer with a background in various leadership roles [3] Group 2: Financial Performance - In the first half of 2025, Huafeng Co., Ltd. achieved total operating revenue of 586 million yuan, a year-on-year increase of 25.89% [5] - The net profit attributable to shareholders was -7.3964 million yuan, a year-on-year decline of 416.6%, primarily due to decreased sales prices and profit margins in both electrode foil and new energy vehicle sectors [5] Group 3: Shareholder Activity - On September 20, 2025, shareholder and general manager Lin Cheng announced plans to reduce his holdings by up to 203.06 million shares, representing 0.96% of the total share capital, within three months starting from October 21, 2025 [5] - On October 29, 2025, Lin Cheng sold 566,000 shares at an average trading price of 13.85 yuan per share [7] - Prior to the suspension, Huafeng Co., Ltd.'s stock price was 13.22 yuan per share, with a total market capitalization of 2.809 billion yuan [8]

Core Viewpoint - The control of Sichuang Medical Technology Co., Ltd. is set to change, with Wei Naixu's Cangnan Xinsheng becoming the controlling shareholder, transitioning from no actual controller to Wei Naixu [1][3]. Group 1: Share Transfer Agreement - The largest shareholder, Lu Nan, signed a share transfer agreement with Cangnan Xinsheng to transfer 62,739,500 shares, representing 5.61% of the total share capital, at a price of 2.872 yuan per share, totaling 180 million yuan [2][4]. - Cangnan Xinsheng will also exercise voting rights for an additional 63,890,185 shares held by Cangnan Si Jia Wulian Intelligent Partnership, representing 5.72% of the total share capital [2][3]. Group 2: Background and Previous Attempts - In April, a previous attempt was made to transfer control to Cangnan Industrial Construction Investment Co., Ltd., but this was terminated due to non-compliance with state asset supervision requirements [4]. - The company has been facing financial difficulties, with cumulative losses exceeding 2.9 billion yuan since 2021, and reported a revenue of 604 million yuan with a loss of 4.76 million yuan in the first three quarters of 2025 [4][5]. Group 3: Future Implications - The share transfer and voting rights delegation are subject to compliance review by the Shenzhen Stock Exchange and require approval from the shareholders' meeting, indicating uncertainty in the final implementation [3]. - The involvement of state-owned capital is expected to leverage resources for the long-term stable development of the company [3].

Core Viewpoint - The control change of Weiguang Biological (002880.SZ) has become a focal point in the regulatory review of its stock issuance to specific targets, with uncertainties surrounding the completion of necessary agreements and approvals [1][2]. Group 1: Control Change Background - In June 2023, Weiguang Biological's controlling shareholder, Guangming District State-owned Assets Supervision and Administration Commission, signed a cooperation agreement with China National Pharmaceutical Group to establish a joint venture with a 49:51 equity ratio, which would result in China National Pharmaceutical becoming the actual controller of the company [1]. - The prerequisites for this control change include signing a supplementary cooperation agreement, a non-compensatory transfer agreement, completing the registration of the joint venture, and passing state-owned assets approval and antitrust review, none of which have been completed as of now [1]. Group 2: Current Status and Commitments - The company explained that the control change has stalled due to complex negotiations involving multiple parties, and there is uncertainty regarding the future progress of this change [1]. - Recent developments indicate that both Guangming District State-owned Assets and China National Pharmaceutical have committed not to push for a control change before the issuance and listing process is completed, which is legally binding and aims to ensure stability during the issuance period [1]. - Regarding the subscription arrangement for the current issuance, China National Pharmaceutical and its affiliates have not expressed any intention to subscribe or signed relevant agreements, and Guangming District State-owned Assets has also clarified that it will not participate in this subscription [1]. Group 3: Future Control Change Risks - The company has clarified that there is no possibility of a control change during the current issuance period, and even if the control change is pursued later, China National Pharmaceutical has committed not to adjust the fundraising projects, thereby maintaining the company's independent decision-making authority in operations and management [2]. - This commitment is expected to prevent any significant adverse impact on existing business operations and fundraising projects, not constituting a substantive obstacle to the current issuance [2].

Core Points - Two companies, Huiyuan Communication and Hualan Group, are undergoing changes in control and will resume trading on November 19, 2025 [2][3] - Aik Shares is planning to issue shares to acquire assets and will be suspended from trading starting November 19, 2025 [5] - ST Zhengping's stock has seen a significant increase of 221.93% from September 1 to November 18, 2025, leading to a suspension for verification [6] - Tianyima plans to acquire 98.5632% of Xingyun Kaiwu for 1.1885 billion yuan and will issue shares to raise up to 155 million yuan [9] Group 1: Control Changes - Huiyuan Communication plans to issue up to 53.65 million shares at 11.37 yuan per share, raising a total of up to 610 million yuan, with the proceeds used for working capital [2] - Hualan Group's actual controllers will transfer a total of 851.13 million shares (5.79% of total shares) to Xutong Investment at a price of 20.41 yuan per share, totaling 174 million yuan [3] Group 2: Suspensions and Resumptions - Aik Shares will be suspended from trading as it plans to issue shares and cash to acquire Dongguan Silicon Xiang Insulation Materials Co., Ltd. [5] - ST Zhengping's stock will be suspended for verification due to its stock price significantly deviating from fundamentals [6] - ST Dongyi has completed its verification work and will resume trading on November 19, 2025 [11] Group 3: Major Asset Restructuring - Tianyima is planning a major asset restructuring by acquiring a majority stake in Xingyun Kaiwu for 1.1885 billion yuan [9] - Meng Tian Home has terminated its asset restructuring and control change plans, leading to its resumption of trading [9] Group 4: Fundraising Activities - Jin An Guo Ji plans to raise up to 1.29995 billion yuan through a private placement for a high-grade copper-clad laminate project [9] - Wan Tong Technology is also planning a private placement to raise up to 920 million yuan for working capital [9]

宣告易主国资终止的同时，思创医惠"火速"披露新的易主方案，公司董事兼总经理魏乃绪成为新的接盘 方。受该消息刺激，11月18日，思创医惠盘中冲上涨停。出生于1981年的魏乃绪，在温州当地颇具名 气，旗下企业码尚科技在全国中小企业股份转让系统挂牌。如今随着魏乃绪的入主，思创医惠也将终结 无主状态。易主背后，思创医惠连续四年净利亏损、涉嫌欺诈发行案尚未终结，摆在魏乃绪面前的难题 并不算少。魏乃绪能否以其在码尚科技积累的实业经验与资本智慧，为思创医惠打开一片新天地，市场 正拭目以待。 归属净利润连亏四年 筹划易主背后，思创医惠业绩承压明显，归属净利润已连续四年出现亏损。 财务数据显示，2021—2024年，思创医惠营收分别约9.63亿元、11.16亿元、10.06亿元、6.91亿元；对应 实现的归属净利润分别约-6.85亿元、-8.78亿元、-8.74亿元、-5.02亿元。 易主刺激股价涨停 11月18日，思创医惠高开高走，盘中冲上涨停。 交易行情显示，11月18日，思创医惠高开0.8%，开盘价报3.78元/股，盘中股价不断上攻至涨停，最终 收于涨停价4.5元/股，涨幅为20%。全天成交金额为8.72亿元，换手率为1 ...